Six Months of Progress on the Precision Medicine Initiative
By Brian Deese & Stephanie Devaney,
Office of Science and Technology Policy
| 07. 08. 2015
Untitled Document
In January 2015, President Obama launched the Precision Medicine Initiative (PMI), a bold new research effort to revolutionize how we improve health and treat disease. Precision medicine is about empowering both patients and health care providers with the information and tools they need to tailor treatment and prevention strategies to patients' unique characteristics.
When he launched the PMI, President Obama called for all hands on deck to continue the kinds of progress that are already beginning to transform the ways we treat diseases such as cancer. Patients with breast, lung, and colorectal cancers, as well as melanomas and leukemias, routinely undergo molecular testing as part of their care, enabling physicians to select treatments that improve chances of survival and reduce exposure to adverse effects. This is precision medicine in action. But there is so much more promise and potential to be unlocked – and we need to extend the successes we’ve seen to other diseases that affect Americans and people around the world.
Today, to mark six months of progress to advance the PMI, the White House is...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...